On 18 February 2020 , the Chinese National Medical Products Administration ( analogous to the U.S. FDA ) approved the antiviral drug Favilavir ( formerly Fapinavir ) for use against COVID-19 .
The Chinese National Medical Products Administration , comparable to the U.S. FDA , approved the drug Fapinavir for use against the 2019-20 coronavirus pandemic .